Celltrion Inc
KRX:068270

Watchlist Manager
Celltrion Inc Logo
Celltrion Inc
KRX:068270
Watchlist
Price: 176 900 KRW 0.74%
Market Cap: 36.7T KRW
Have any thoughts about
Celltrion Inc?
Write Note

Celltrion Inc
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Celltrion Inc
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Celltrion Inc
KRX:068270
Short-Term Investments
â‚©167.2B
CAGR 3-Years
123%
CAGR 5-Years
3%
CAGR 10-Years
40%
SK Bioscience Co Ltd
KRX:302440
Short-Term Investments
â‚©1.1T
CAGR 3-Years
84%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Short-Term Investments
â‚©1.8B
CAGR 3-Years
-56%
CAGR 5-Years
-20%
CAGR 10-Years
-29%
H
Hugel Inc
KOSDAQ:145020
Short-Term Investments
â‚©271.9B
CAGR 3-Years
-18%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Short-Term Investments
â‚©111B
CAGR 3-Years
18%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Short-Term Investments
â‚©126.7B
CAGR 3-Years
-13%
CAGR 5-Years
25%
CAGR 10-Years
N/A
No Stocks Found

Celltrion Inc
Glance View

Market Cap
36.7T KRW
Industry
Biotechnology

Celltrion Inc. is a South Korean biopharmaceutical company that has made significant strides in the development and commercialization of biosimilars, monoclonal antibodies, and novel therapeutics. Established in 2002, the company has positioned itself as a key player in the global pharmaceutical landscape, particularly known for its commitment to making biological drugs more accessible and affordable. With a robust pipeline of products targeting conditions such as autoimmune diseases, cancer, and infectious diseases, Celltrion leverages state-of-the-art biotechnology and a strong emphasis on research and development. This focus not only enhances its product offerings but also champions the company’s mission of improving patient outcomes worldwide. As the global market for biosimilars continues to expand, driven by increasing healthcare costs and an aging population, Celltrion stands at the forefront, equipped with a solid operational framework and a strategic partnership approach. The company’s flagship products, like Remsima, a biosimilar to Remicade, have achieved notable success, gaining approval in numerous countries and establishing a strong revenue stream. With its plans to diversify its product portfolio, including innovative therapies in oncology, Celltrion is poised for growth. For investors, this translates into a promising opportunity to tap into a company that not only prioritizes innovation but also operates within a rapidly evolving market characterized by increasing demand for more affordable biologics.

Intrinsic Value
187 345.57 KRW
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Celltrion Inc's Short-Term Investments?
Short-Term Investments
167.2B KRW

Based on the financial report for Jun 30, 2024, Celltrion Inc's Short-Term Investments amounts to 167.2B KRW.

What is Celltrion Inc's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
40%

Over the last year, the Short-Term Investments growth was 502%. The average annual Short-Term Investments growth rates for Celltrion Inc have been 123% over the past three years , 3% over the past five years , and 40% over the past ten years .

Back to Top